Xilio Therapeutics (XLO) Price & Analysis

Compare

216 Followers

XLO Stock Chart & Stats

$0.59

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$0.59

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$0.50 - $1.18

Previous CloseN/A

Volume162.24K

Average Volume (3M)493.56K

Market Cap

$38.77M

Enterprise Value-$67.90M

Total Cash (Recent Filing)$103.76M

Total Debt (Recent Filing)$7.26M

Price to Earnings (P/E)―

Beta0.30

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding73,457,200

10 Day Avg. Volume359,286

30 Day Avg. Volume493,558

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)2.90

Price to Sales (P/S)8.06

P/FCF Ratio-2.78

Enterprise Value/Market Cap-1.75

Enterprise Value/Revenue-2.14

Enterprise Value/Gross Profit-4.21

Enterprise Value/Ebitda1.20

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)$37.80M

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentManagement aims to partner with other companies to advance the clinical development of vilastobart, showing a proactive approach in expanding potential market reach.

Financial StabilityThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.

InnovationXilio is on track with strategic nominations for developing targeted therapies, reflecting a clear pipeline and focus on innovation.

Bears Say

Financial PerformanceXilio reported a net loss of $16.3 million, indicating financial challenges that need to be addressed.

Strategic PartnershipsFinding the right partner quickly is critical for both the asset and the company.

Xilio Therapeutics News

Xilio Therapeutics announces inducement grants

Xilio Therapeutics (XLO) announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050...

4d ago

XLO

XLO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Xilio Therapeutics Inc (XLO) is scheduled to report 4th quarter earnings on 03/04/2026. Regarding Q4 estimates, Wall Street...

4d ago

XLO

Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split

The latest update is out from Xilio Therapeutics ( ($XLO) ). On February 23, 2026, Xilio Therapeutics, Inc....

10d ago

XLO

Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing

Xilio Therapeutics ( ($XLO) ) just unveiled an announcement. On February 11, 2026, Xilio Therapeutics announced the pricing...

21d ago

XLO

Xilio Therapeutics Announces Leadership Transition and Pipeline Updates

Xilio Therapeutics ( ($XLO) ) has provided an announcement. On January 8, 2026, Xilio Therapeutics reported a series...

2M ago

XLO

Xilio Therapeutics highlights upcoming milestones, corporate updates

Xilio Therapeutics (XLO) highlighted upcoming milestones and recent corporate updates. “2025 was marked by robust execution at Xilio...

2M ago

XLO

Xilio Therapeutics Extends Cash Runway Into 2027

An announcement from Xilio Therapeutics ( ($XLO) ) is now available. In June 2025, Xilio Therapeutics issued 66,676,000...

2M ago

XLO

Xilio Therapeutics Approves 2025 Stock Incentive Plan

The latest update is out from Xilio Therapeutics ( ($XLO) ). On November 21, 2025, Xilio Therapeutics held...

3M ago

XLO

Xilio Therapeutics Reports Revenue Growth Amidst Challenges

Xilio Therapeutics Inc ( ($XLO) ) has released its Q3 earnings. Here is a breakdown of the information...

4M ago

XLO

Xilio Therapeutics expects cash to fund operations into Q1 of 2027

Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of September 30,...

4M ago

XLO

Xilio Therapeutics reports Q3 EPS (11c) vs (22c) last year

Reports Q3 revenue $19.066M vs $2.263M last year. “As we advance our robust pipeline of innovative masked immunotherapies,...

4M ago

XLO

Xilio Therapeutics presents new data across portfolio at SITC

Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked...

4M ago

XLO

Xilio Therapeutics announces new data on Phase 2 trial of vilastobart

Xilio Therapeutics (XLO) announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced...

4M ago

XLO

Xilio Therapeutics Transfers Listing to Nasdaq Capital Market

Xilio Therapeutics ( ($XLO) ) just unveiled an update. On October 2, 2025, Xilio Therapeutics received approval from...

5M ago

XLO

XLO FAQ

What was Xilio Therapeutics Inc’s price range in the past 12 months?

Xilio Therapeutics Inc lowest stock price was $0.50 and its highest was $1.18 in the past 12 months.

What is Xilio Therapeutics Inc’s market cap?

Xilio Therapeutics Inc’s market cap is $38.77M.

When is Xilio Therapeutics Inc’s upcoming earnings report date?

Xilio Therapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 62 days.

How were Xilio Therapeutics Inc’s earnings last quarter?

Currently, no data Available

Is Xilio Therapeutics Inc overvalued?

According to Wall Street analysts Xilio Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xilio Therapeutics Inc pay dividends?

Xilio Therapeutics Inc does not currently pay dividends.

What is Xilio Therapeutics Inc’s EPS estimate?

Xilio Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Xilio Therapeutics Inc have?

Xilio Therapeutics Inc has 73,457,200 shares outstanding.

What happened to Xilio Therapeutics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Xilio Therapeutics Inc?

Currently, no hedge funds are holding shares in XLO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Xilio Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-908.28%

Trailing 12-Months

Asset Growth

79.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xilio Therapeutics Inc

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.